CEST

Implantica adds another RefluxStop™ center in Spain

Retrieved on: 
Monday, December 18, 2023
CEST, Club Universitario de Deportes, Patient, Certification, Quality of life, Medical device, Arms industry, GERD

), a medtech company at the forefront of bringing advanced technology into the body, announces another key public hospital in Spain successfully completed its first RefluxStop™ procedures.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces another key public hospital in Spain successfully completed its first RefluxStop™ procedures.
  • Dr. Pablo Priego performed his first two RefluxStop™ procedures at Universitario Ramón y Cajal Hospital in Madrid, Spain.
  • The RefluxStop™ procedure aims to address the root cause of acid reflux or GERD without affecting the food passageway, allowing the body to function normally.
  • Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

EQS-News: Pyrum Innovations AG publishes financial figures for the first nine months of 2023

Retrieved on: 
Thursday, December 14, 2023
CEST, Research, REMONDIS, Czech Republic, Partnership, ISIN, Acquisition, Dillingen (Saar) station, Zonaria pyrum, EUR, BASF, Deutsch, Plant, ELT, Letter, Dillingen, Saarland, Recycling, RCB, Lithium, Airline, Dillingen

Sales in the first nine months totalled EUR 842 thousand, around 18% higher than in the same period of the previous year (9M 2022: EUR 714 thousand).

Key Points: 
  • Sales in the first nine months totalled EUR 842 thousand, around 18% higher than in the same period of the previous year (9M 2022: EUR 714 thousand).
  • Own work capitalised amounted to EUR 9,828 thousand (9M 2022: EUR 13,171 thousand) as construction of the plant expansion in Dillingen progressed according to plan.
  • Cash and cash equivalents as of 30 September 2023 amounted to EUR 4,410 thousand (31 December 2022: EUR 12,519 thousand).
  • For the full year 2023, the management is currently expecting sales of between EUR 1.1 million and EUR 1.5 million.

EQS-News: Endor AG publishes figures for the the third quarter of 2023 and provides an outlook on further developments

Retrieved on: 
Thursday, December 14, 2023
ERP, CEST, EUR, SONY, Black Friday, Landshut, Tax, Depreciation, Investment, CSL, Black, EBITDA, EBIT, Video game, Film industry, Endor

Accordingly, the global provider of equipment for racing simulations in the simracing market generated consolidated revenues of EUR 64.7 million in the first nine months 2023.

Key Points: 
  • Accordingly, the global provider of equipment for racing simulations in the simracing market generated consolidated revenues of EUR 64.7 million in the first nine months 2023.
  • The positive development in the single third quarter is due to the market entry into the mainstream market with the CSL DD in June 2023.
  • In addition, Endor developed further products in the first nine months of 2023, some of which will be presented in the fourth quarter of 2023.
  • Endor AG will hold an investor call on the current figures on 30 November 2023 at 14:00 (CEST).

Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status

Retrieved on: 
Tuesday, December 12, 2023
NDI, Risk, Incidence, Executive Committee, Industrial Affairs Committee (Iceland), Dietary supplement, FDA, Letter, CEST, Regulatory News Service, US Foods, Food, Safety

La Rochelle, December 11, 2023 (08:00 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has received approval from the Food and Drug Administration (FDA) for New Dietary Ingredient (NDI) status for a plant extract present in all its TOTUM products.

Key Points: 
  • La Rochelle, December 11, 2023 (08:00 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has received approval from the Food and Drug Administration (FDA) for New Dietary Ingredient (NDI) status for a plant extract present in all its TOTUM products.
  • The US Food and Drug Administration (FDA) imposes specific requirements on manufacturers and distributors wishing to market dietary supplements containing "new dietary ingredients".
  • Sébastien PELTIER, CEO and co-founder, emphasizes: "Obtaining the New Dietary Ingredient (NDI) status for this plant extract is a gratifying milestone, albeit expected, marking the conclusion of a standard authorization process.
  • This comes at a time when the growing incidence of metabolic and cardiovascular diseases worldwide poses a public health challenge."

The EBA consults on draft technical standards on supervisory colleges under MiCAR

Retrieved on: 
Thursday, November 9, 2023
Crypto, Policy, European Securities and Markets Authority, The, Emergency medical technician, CEST, Exercise, European Central Bank, Central bank, ART, RTS, European, EMT, Adoption, European Banking Authority, Article, EBA, Cryptocurrency, EU

The draft RTS also specify the general conditions for the functioning of supervisory colleges under MiCAR.

Key Points: 
  • The draft RTS also specify the general conditions for the functioning of supervisory colleges under MiCAR.
  • This consultation together with other consultations papers published today form part of the third batch of MiCAR policy products.
  • Article 119(1) of MiCAR requires the EBA to establish, manage and chair a consultative supervisory college for each issuer of a significant ART or of a significant EMT.
  • The role of supervisory colleges under MiCAR is to facilitate the exercise of the EBA’s supervisory tasks under MiCAR and to facilitate the cooperation and exchange of information among its members.

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Decentralized finance, Progression-free survival, The New England Journal of Medicine, Plantar fibromatosis, CEST, Medicine, Annual general meeting, Cancer, Therapy, Pain, Disability, Pharmaceutical industry, Medical imaging, Patient

STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the presentation of additional data from the Phase 3 DeFi trial at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, being held November 1-4, 2023. These data demonstrate the impact of nirogacestat, an investigational gamma secretase inhibitor, on physical and role functioning in adults with desmoid tumors. Data from the DeFi trial demonstrated statistically significant and clinically meaningful improvements across all primary and key secondary endpoints and were previously presented at leading medical congresses and published in the March 9, 2023 edition of the New England Journal of Medicine.1-3

Key Points: 
  • These data demonstrate the impact of nirogacestat, an investigational gamma secretase inhibitor, on physical and role functioning in adults with desmoid tumors.
  • “We are pleased that the robust data from our Phase 3 DeFi trial demonstrated that nirogacestat provided clinically meaningful improvements in key patient-reported outcomes, including pain as well as both physical and role functioning.
  • Nirogacestat also achieved a significant and clinically meaningful improvement in physical and role functioning status, a key secondary endpoint, compared with placebo at Cycle 10 (p
  • Nirogacestat significantly improved mean physical functioning score from baseline per the EORTC QLQ-C30 PF subscale compared with placebo at the pre-specified time point.

DuPont Collaborates with STMicroelectronics (ST) to Develop New Smart Wearable Device Concept for Monitoring Biosignals

Retrieved on: 
Thursday, November 2, 2023
Well, MEMS, MEDICA Trade Fair, MEDICA, ECG, St. Jude Medical, NYSE, Health care, Adhesive, SCG, Original equipment manufacturer, CEST, Research, STMicroelectronics, STM, DuPont, Electronics, Safety, Vital signs, Patient, Television, 3D printing, Medical device

WILMINGTON, Del., Nov. 2, 2023 /PRNewswire/ -- DuPont (NYSE:DD) today announced that DuPont™ Liveo™ Healthcare Solutions is collaborating with STMicroelectronics (NYSE: STM), a global leader in semiconductor technology serving customers across the spectrum of electronics applications, to develop a new smart wearable device concept for remote biosignal-monitoring.

Key Points: 
  • DuPont™ Liveo™ Healthcare and ST combine to create a new concept in wearable biosignal-monitoring devices that merges patient comfort with high performance.
  • WILMINGTON, Del., Nov. 2, 2023 /PRNewswire/ -- DuPont (NYSE:DD) today announced that DuPont™ Liveo™ Healthcare Solutions is collaborating with STMicroelectronics (NYSE: STM), a global leader in semiconductor technology serving customers across the spectrum of electronics applications, to develop a new smart wearable device concept for remote biosignal-monitoring.
  • "The wearable device concept that resulted from the collaboration between DuPont and ST is the DuPont™ Liveo™ Smart Biosensing Patch prototype, which employs multifunctional microsensors and control electronics from ST embedded in a flexible patch design from DuPont."
  • Whether for drug delivery or smart monitoring devices, DuPont™ Liveo™ Healthcare Solutions helps enable positive patient outcomes through increasingly advanced medical technology.

EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2023

Retrieved on: 
Friday, October 27, 2023
Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, PIN, Workforce, Acquisition, CEST, EBIT, Magazine, Flow cytometry, Weakness, Fine chemical

The STRATEC Group generated consolidated sales of € 187.7 million in the first nine months of 2023 (9M/2022: € 207.7 million).

Key Points: 
  • The STRATEC Group generated consolidated sales of € 187.7 million in the first nine months of 2023 (9M/2022: € 207.7 million).
  • Natech Plastics, which was consolidated for the first time as of July 1, 2023, contributed 130 basis points to consolidated sales.
  • Adjusted EBIT for the first nine months of 2023 therefore amounts to € 16.2 million (9M/2022: € 38.1 million).
  • To mark the publication of the final results for the first nine months of 2023, STRATEC will be holding a conference call in English at 2.00 p.m. (CEST) today, Friday, October 27, 2023.

Aker BP reports third quarter 2023 results

Retrieved on: 
Friday, October 27, 2023
USD, Q&A, Accounting, Growth, Alvheim FPSO, Global warming potential, Aker BP, CEST, Comment, Renewable energy

FORNEBU, Norway, Oct. 27, 2023 /PRNewswire/ -- Aker BP continued its strong performance in the third quarter of 2023, bolstered by high operational efficiency, increased oil prices, and rigorous cost control, and maintained its standing as an industry leader in low greenhouse gas emissions.

Key Points: 
  • FORNEBU, Norway, Oct. 27, 2023 /PRNewswire/ -- Aker BP continued its strong performance in the third quarter of 2023, bolstered by high operational efficiency, increased oil prices, and rigorous cost control, and maintained its standing as an industry leader in low greenhouse gas emissions.
  • The company's field development projects are progressing according to plan, and its exploration activities resulted in two new discoveries in the quarter.
  • Production on track: Oil and gas production was 450 mboepd in the quarter.
  • Low emissions: Aker BP continues to lead the oil and gas industry with greenhouse gas emissions of only 2.8 kg CO2e per boe.

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

Retrieved on: 
Thursday, October 26, 2023
Q&A, RNA, Spleen, Congress, Liver, Moderna, CEST, DNA, European Society of Gene and Cell Therapy, Tissue, Cell, Gene, Webcast, Messenger, LNP, ESGCT, Generation, Patient, NHP, Dietary supplement, Vaccine

Generation Bio will present these data at the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress in Brussels, Belgium at 4:40 p.m. CEST today.

Key Points: 
  • Generation Bio will present these data at the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress in Brussels, Belgium at 4:40 p.m. CEST today.
  • Slides from the presentation will be made available on Generation Bio’s website following the presentation.
  • “Furthermore, species translation for the stealth LNP underlying our ctLNP platform is highly encouraging as we continue to move forward with our cell-targeting work.
  • Registration information for the webcast R&D deep dive can be found on the Events page of Generation Bio’s investor website.